PICC Asset Management, established in 2003 and headquartered in Shanghai, is a prominent insurance asset management company in China, initiated by the China People's Insurance Group. With nearly 900 billion yuan in assets under management, it is authorized by regulatory bodies to engage in various investment activities, including stocks, bonds, real estate, and infrastructure. The company focuses on a comprehensive approach to asset management, emphasizing asset-liability matching and risk management. Over the years, PICC has diversified its offerings, engaging in third-party business development, special account management, and equity investments. It has built a robust portfolio that includes annuity and pension products while fostering partnerships with major financial institutions and enterprises. The firm is dedicated to professional growth and standardized operations, having established a tripartite deposit management mechanism to ensure investment security. By maintaining a strong resource base and a skilled professional team, PICC Asset Management aims to create long-term stable investment returns for its clients and position itself as a competitive player in both domestic and international markets.
Doma Biopharmaceutical is a biotechnology company focused on drug research and development. It utilizes proprietary platforms for the development of fully human monoclonal and bispecific antibodies. The company has integrated in vivo drug efficacy screening with robust clinical development expertise to enhance the efficiency of the drug development process. By streamlining these processes, Doma Biopharmaceutical aims to assist global partners in producing a diverse range of antibody-based therapeutics.
Shanghai InGeek Cyber Security Co.,Ltd provides consulting, implementation, operation, maintenance, and software development services for information, network, and system security. The company was founded in 2002 and is headquartered in Shanghai, China. Shanghai InGeek Cyber Security Co.,Ltd operates as a subsidiary of Shanghai Yinji Information Technology Co., Ltd.
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Tongxin Medical Equipment
Series D in 2022
Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency
NeoCura is a company that specializes in developing AI-based platforms and diagnostic tests for cancer therapy. Founded in 2017 and headquartered in Shenzhen, China, NeoCura offers several advanced tools, including the NeoCura AI ALPINE platform for tumor neoantigen prediction, which identifies potential neoantigen candidates. The NeoCura AI EVEREST platform focuses on validating these neoantigens to enhance patient outcomes. Additionally, NeoCura TP serves as an intelligent companion diagnostic that forecasts treatment options for immunotherapy based on tumor mutational burden. The company also provides an AI-enabled immunotherapy solution that targets patient-specific neoantigens. In addition to these platforms, NeoCura offers diagnostics and medical laboratory services, leveraging AI to improve the diagnosis and treatment of cancer patients.
Vastai Technologies specializes in the development of semiconductor chips tailored for computer vision, video processing, and various artificial intelligence applications. The company's innovative products are engineered to enhance the computing capabilities of AI visual applications, allowing manufacturers of computer devices to integrate advanced chip technology into their offerings. By focusing on optimizing performance in these specific areas, Vastai Technologies aims to support the growing demand for efficient and powerful AI solutions in the market.
Weishi Energy is a hydrogen fuel cell product research and development manufacturer, focusing on the market operation of hydrogen fuel cell technology, and is committed to promoting the low-carbon sustainable development of human energy. It is mainly engaged in the research and development, production and sales of hydrogen fuel cell products. At present, Weishi Energy has deployed five R&D centers in Shanghai, Baoding, Japan, Germany, and Canada. It has established a culturally diverse and technologically advanced R&D team, and strictly follows the V model development process to create vehicle-level fuel cell power systems and components. The company's main products include fuel cell engines, electric stacks, 35MPa/70MPa on-board hydrogen systems, bottle valves and pressure reducing valves, etc.
Svolt Energy Technology Co., Ltd. is a high-tech new energy company that specializes in energy technology, including electric vehicle battery (EVB) materials, cells, modules, PACK, BMS, energy storage system (ESS) and solar energy R&D and manufacturing. Headquartered in Wuxi, Jiangsu, SVOLT plans for 7 R&D centers around the globe, with four currently in operation, in Baoding, Korea, Shanghai and India, and three are under construction in the US, Japan and Wuxi. Domestically, SVOLT’s factory is under construction in Changzhou, Jiangsu, which will be operational by the end of 2019 with SOP in February 2020, and will have a capacity of 12GWh in 2020. Roadmap: SVOLT is pioneering the introduction of prismatic stacking batteries, making it the world’s first high-speed stacking prismatic battery maker. SVOLT aims to finish stacking one cell in 0.25 seconds in one single station. In contrast to the same type of winding process, the energy density of SVOLT stacking batteries improves 5%, the cycle life improves 10% and the cost reduces 15%.
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
Jenscare Biotech
Venture Round in 2021
A Biotech Company based In Ningbo.
GeneQuantum Healthcare
Series C in 2021
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company that focuses on the research and development of innovative Bio-therapeutics. GeneQuantum was founded in August 2013 at Suzhou Industrial Park, and has built-up a world-class bio-conjugation technology platform, focusing on developing series of next generation anti-tumor Antibody-Drug-Conjugates (ADCs) with best-in-class potential. Securing this round of financing will significantly promote the development of current ADC candidates towards IND filling in both US and China, meanwhile further expanding the company's product pipeline.
Abogen Biosciences
Series B in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Operator of elderly care facilities in China. The company focuses on providing a comprehensive care system to build a community based platform for elderly care. The company's services include daytime elderly care, 24-hour elderly care, home care, comprehensive elderly care and nursing homes.
Rimag provides medical imaging service. The company engages in medical imaging center operation, relevant cloud technology development, and talent training. The company was founded in 2014 and is based in Shenzhen, China.
Xiangji Tech, also known as Xiangji Zhiyuan (Wuhan) Technology Co., Ltd., is a provider of commercial weather reports and analytics based in Beijing, China. Founded in 2014, the company operates as a subsidiary of Wuhan Tianyou Xiangji Technology Center. Xiangji Tech specializes in meteorological services, utilizing advanced technologies such as cloud computing, big data, and the Internet of Things (IoT). The company offers accurate weather forecasts and analytics to help clients mitigate risks associated with adverse environmental conditions, thereby enhancing operational safety and efficiency. Its services cater to various sectors, making it a significant player in the domestic meteorological services market in China.
UCAR, established in 1999 and headquartered in Tianjin, China, is a prominent provider of on-demand car-hailing services. The company utilizes mobile internet technology and big data to connect customers with local drivers via a smartphone platform. UCAR offers both chauffeured car services and car rentals, featuring an in-house fleet and licensed drivers. The company's commitment to safety and quality is reflected in its rigorous driver screening processes and vehicle standards. UCAR employs advanced technologies to monitor driver behavior, ensuring a reliable and secure experience for users, along with privacy protection and prompt compensation in the event of accidents.
Xikang Cloud Hospital Holdings Inc, based in Beijing, China, specializes in cloud-based medical and healthcare management services. The company has developed China's first city-specific cloud hospital platform, enabling the delivery of various Internet medical services such as online hospital consultations, remote medical assistance, smart family doctor services, and Internet home care. Xikang also offers health management services and smart healthcare products. Its operations are divided into four segments: cloud hospital platform services, Internet medical services, health management services, and smart healthcare products, with the majority of its revenue generated from health management services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.